Form 4: Adverum Biotechnologies Director Acquires Stock Options
SEC Form 4 Filing
C. David Nicholson, a director of Adverum Biotechnologies, acquired stock options exercisable for 10,520 shares of common stock on June 17, 2024.
Summary
- On June 17, 2024, C. David Nicholson, a director of Adverum Biotechnologies, acquired stock options for 10,520 shares.
- The exercise price of these options is $7.32.
- The options vest on the earlier of June 17, 2025, or the 2025 annual meeting of stockholders, subject to accelerated vesting upon a change of control and continued service with the Issuer.
- Following the transaction, Nicholson directly owns 10,520 derivative securities.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of options by a director can be seen as a mildly positive signal, but it's a routine event.
Positives
- A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.
Future Outlook
The vesting of the options is contingent upon continued service and may accelerate upon a change of control, suggesting a focus on long-term commitment and potential strategic events.
Industry Context
This is a routine disclosure related to insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.
Comparison to Industry Standards
- Stock option grants to directors are a common practice in the biotechnology industry to align their interests with those of shareholders.
- The vesting schedule and terms are typical for such grants, often tied to continued service and company performance.
- Comparing the size of the grant to those of directors at similar-sized biotech companies (e.g., companies with market caps between $50 million and $200 million) would provide further context.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 2024-03-15 | Date of Power of Attorney execution. |
| 2024-06-17 | Date of the stock option transaction. |
| 2024-06-17 | Earliest date the shares subject to the option will vest and become exercisable. |
| 2024-06-20 | Date of signature for the Form 4 filing. |
| 2025 | The 2025 annual meeting of stockholders, which is an alternative vesting date. |
| 2034-06-16 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.